The effect of once-daily Methods The diurnal lOP and sitting POBF were determined for 32 eyes of 19 NTG patients after a washout period. The subjects were treated with 0.005% latanoprost for 3-4 weeks and the measurements repeated.
. The reduction in lOP obtained with latanoprost treatment correlated with the initial lOP after the washout period. This correlation is significant (r = 0.31, P < 0.01). These data are shown in Fig. 2 .
The median POBF prior to treatment was 656 [Ll/min (CI = 588-729). After treatment, the median POBF was 796 [Ll/ min (CI = 697-894). This difference is also significant (p < 0.001).
Discussion
In this study, once-daily 0.005% latanoprost reduced lOP by 18% in patients with NTG. This was accompanied by an increase in POBF of 21 % after 3-4 weeks of treatment.
No patients withdrew from the study as a result of significant ocular or systemic side-effects.
The average lOP reduction of 18% is comparable with previous studies relating to the use of latanoprost in NTG.8,9 The magnitude of lOP reduction is proportional to the initial lOP (Fig. 2) , and this is likely to account for the small variation between the studies. In this study, the reduction was noted after 3-4 weeks of treatment. �   12  13  14  15  16  17  18  19  20  21  22 Average lOP before treatment (mm Hg) Further lOP reduction may also be possible through the combined use of latanoprost with other ocular hypotensive medication.12
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A target lOP reduction of 30% has been advocated previously for the initial management of NTG subjects.13
The percentage lOP reduction achieved with latanoprost monotherapy in our study falls short of this target. Given the small numbers in our study, it is difficult to give accurate predictions of the expected effect of treatment, but the results may act as a guide'to the likely outcome.
An lOP fall in excess of 25% was achieved for 7 of the 32 treated eyes, but 9 eyes had a reduction of less than 15%. Observer error was minimised for Goldmann lOP recording with the use of an opaque shield to prevent simultaneous observation of the tonometer mires and scale? This is not necessary while recording POBF as the data from consecutive ocular pulses is computer analysed and a cut-off standard deviation is applied to all recordings. Although the inter-individual variation in POBF is high, the main value in POBF recording is to document a change within individuals over time. 21 As we have used data from both eyes of some patients, not all the cases in this study are independent. However, sensitivity analysis was performed with data randomly chosen from those patients in whom both eyes were studied and there was no clinically significant difference in either the lOP or POBF results.
This study demonstrates that once-daily treatment with 0.005% latanoprost provides a significant and stable lOP reduction in NTG patients after short-term treatment. This is accompanied by an increase in POBF.
Given the poor effect on lOP in some patients, we would advocate a trial treatment period before commencing long-term therapy. The data from this study are encouraging in the management of NTG, when an adequate lOP reduction is often difficult with medical treatment alone. However, only long-term studies will demonstrate whether these changes are sustained and prevent progressive loss of visual field.
The latanoprost used in this study was supplied by Pharmacia & Upjohn Limited.
